Figure 1. Progressive DA deficiency in Slc6a3^DTR/+ mice.

A) Treatment timeline. B) Weights of treated mice remain stable over time. For all panels, n=mice. For all figures, data are represented as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001, reserpine vs. WT_saline; ^!p<0.05, ^!!p<0.01, ^!!!p<0.001, DAT_dT vs. WT_dT; ^@p<0.05, ^@@p<0.01, DAT_dT-2w vs. DAT_dT-4w; ^$p<0.05, ^$$p<0.01, ^$$$p<0.001, DAT_dT-2w vs. reserpine. C) WT_saline and WT_dT mice show a progressive increase in the latency to fall from the rotarod over 3 consecutive trials. DAT_dT mice show a progressive reduction in rotarod performance. D) Rotarod performance is similar across control groups. Reserpine mice are incapacitated. E) Striatal DA content is depleted 12 hr after reserpine and progressively decreases 2 and F) 4 wk following the first injection of dT. G) DAT_dT-2w mice show impaired balance beam performance. H₁) Open field tests show an increase in ambulations, H₂) rearings, and H₃) stereotypies in DAT_dT-2w mice following 5 daily treatments with L-Dopa. See also Figure S1 and Table S1.